Q2 Earnings Forecast for Immunome Issued By Lifesci Capital

Immunome, Inc. (NASDAQ:IMNM - Free Report) - Analysts at Lifesci Capital lifted their Q2 2025 earnings per share estimates for shares of Immunome in a note issued to investors on Tuesday, June 3rd. Lifesci Capital analyst C. Zhu now forecasts that the company will post earnings of ($0.55) per share for the quarter, up from their previous estimate of ($0.61). Lifesci Capital has a "Outperform" rating and a $20.00 price objective on the stock. The consensus estimate for Immunome's current full-year earnings is ($2.21) per share. Lifesci Capital also issued estimates for Immunome's Q3 2025 earnings at ($0.60) EPS, Q4 2025 earnings at ($0.66) EPS, FY2025 earnings at ($2.34) EPS, Q1 2026 earnings at ($0.75) EPS, Q2 2026 earnings at ($0.75) EPS, Q3 2026 earnings at ($0.62) EPS, Q4 2026 earnings at ($0.58) EPS and FY2026 earnings at ($2.70) EPS.

Several other equities research analysts have also recently issued reports on the stock. Guggenheim decreased their target price on shares of Immunome from $35.00 to $25.00 and set a "buy" rating on the stock in a research report on Thursday, March 20th. Lake Street Capital began coverage on shares of Immunome in a research note on Wednesday, April 2nd. They set a "buy" rating and a $23.00 price target on the stock. Wall Street Zen upgraded shares of Immunome from a "sell" rating to a "hold" rating in a report on Thursday, May 22nd. Stephens restated an "overweight" rating and set a $30.00 price objective on shares of Immunome in a report on Thursday, March 20th. Finally, Wedbush reiterated an "outperform" rating and issued a $21.00 target price (down previously from $33.00) on shares of Immunome in a report on Tuesday, May 13th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company's stock. Based on data from MarketBeat.com, Immunome has an average rating of "Moderate Buy" and a consensus price target of $23.33.

Immunome Trading Up 0.1%

IMNM traded up $0.01 during midday trading on Thursday, hitting $9.13. The company's stock had a trading volume of 1,228,054 shares, compared to its average volume of 916,775. Immunome has a 52-week low of $5.15 and a 52-week high of $16.81. The firm has a 50-day moving average price of $7.82 and a two-hundred day moving average price of $9.51. The firm has a market cap of $794.42 million, a P/E ratio of -1.13 and a beta of 1.94.

Immunome (NASDAQ:IMNM - Get Free Report) last released its earnings results on Monday, May 12th. The company reported ($0.52) EPS for the quarter, beating the consensus estimate of ($0.66) by $0.14. Immunome had a negative return on equity of 48.63% and a negative net margin of 3,014.59%. The firm had revenue of $2.93 million during the quarter, compared to analyst estimates of $0.46 million.

Insider Activity

In related news, CEO Clay B. Siegall acquired 137,100 shares of the business's stock in a transaction on Wednesday, March 26th. The shares were bought at an average cost of $7.29 per share, with a total value of $999,459.00. Following the completion of the transaction, the chief executive officer now directly owns 806,736 shares of the company's stock, valued at $5,881,105.44. This trade represents a 20.47% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Jean Jacques Bienaime bought 5,000 shares of the stock in a transaction dated Tuesday, June 3rd. The stock was bought at an average price of $9.38 per share, with a total value of $46,900.00. Following the purchase, the director now owns 36,415 shares of the company's stock, valued at approximately $341,572.70. This represents a 15.92% increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders have acquired 161,400 shares of company stock valued at $1,207,395. Company insiders own 8.60% of the company's stock.

Institutional Trading of Immunome

A number of hedge funds have recently made changes to their positions in the company. BNP Paribas Financial Markets purchased a new position in shares of Immunome in the fourth quarter valued at $70,000. KLP Kapitalforvaltning AS acquired a new position in Immunome in the 4th quarter worth $75,000. AlphaQuest LLC boosted its position in Immunome by 786,700.0% in the 4th quarter. AlphaQuest LLC now owns 7,868 shares of the company's stock valued at $84,000 after buying an additional 7,867 shares during the last quarter. Tower Research Capital LLC TRC grew its stake in shares of Immunome by 482.0% during the fourth quarter. Tower Research Capital LLC TRC now owns 8,608 shares of the company's stock valued at $91,000 after acquiring an additional 7,129 shares in the last quarter. Finally, Aquatic Capital Management LLC acquired a new stake in shares of Immunome during the fourth quarter valued at about $95,000. Hedge funds and other institutional investors own 44.58% of the company's stock.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.